Nexalin Technology reports secondary analysis improvements in Alzheimer’s trial data
Nexalin Technology said further ADAS-Cog data analysis from its randomized, sham-controlled trial found improvements tied to memory domains in Alzheimer’s patients. The Company plans to use ADAS-Cog subscale results for a planned U.S. Alzheimer’s pilot study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.